China’s investigation of how western drug companies operate in the country broadened yesterday as GlaxoSmithKline admitted wrongdoing by staff.
Abbas Hussain, GSK’s president of international operations, said that senior China-based executives “appear to have acted outside of our processes and controls which breaches Chinese law”.
In a nod to the Chinese government’s concerns about soaring healthcare costs, Mr Hussain pledged that GSK would reduce drug prices in China by making changes to its operating model that would lower costs.
您已閱讀21%（535字），剩余79%（2062字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。